RxDoctor Payments DataLook up a doctor →

Victor Gonzalez, MD

Retina Specialist · McAllen, TXNPI 1871599100

Payments from drug & device makers

$2,140,360in general payments, 2019–2025

Across 915 payments — averaging $2339.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$595K
  • Genentech, Inc.$311K
  • Boehringer Ingelheim International GmbH$130K
  • Regeneron$118K
  • Apellis Pharmaceuticals, Inc.$110K
  • Astellas Pharma Global Development$109K
  • plus $765K from 54 others
$2,858in research payments, 2019–2025

Across 3 payments — averaging $952.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alimera Sciences, Inc.$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis46$595,445
Genentech, Inc.43$311,257
Boehringer Ingelheim International GmbH69$130,468
Regeneron16$118,371
Apellis Pharmaceuticals, Inc.43$109,850
Astellas Pharma Global Development11$109,421
US Retina LLC11$108,938
Roche TCRC, Inc.10$80,264
Boehringer Ingelheim9$67,537
Alcon Research LLC13$53,934
Eyepoint US, Inc.24$47,778
Bausch & Lomb Americas Inc.82$39,934
Aerie Pharmaceuticals, Inc.3$32,168
GSK4$30,030
Beaver-visitec International, Inc.4$29,081
Boehringer Ingelheim Finland Ky30$26,065
Bausch & Lomb, A Division Of Bausch Health US, LLC57$25,442
Sun Pharmaceutical Industries Inc.14$24,345
Alnylam Pharmaceuticals Inc.7$23,938
ANI Pharmaceuticals, Inc.7$21,020
Rxsight Inc17$20,526
AbbVie(2 entities)75$18,471
Alimera Sciences, Inc.40$18,231
Regeneron Healthcare Solutions, Inc.13$15,767
F. Hoffmann-la Roche AG1$13,444
Thrombogenics, Inc.7$10,309
Novartis Pharma AG4$8,682
Johnson & Johnson Surgical Vision, Inc.27$8,398
Mallinckrodt Enterprises LLC1$6,750
Harrow Eye, LLC11$6,544
Lumibird Medical Inc.3$6,122
Genentech USA, Inc.18$4,538
Alcon55$2,869
Samsara Vision3$2,800
Cardinal Health 108 LLC4$1,790
Iridex Corporation1$1,750
Glaukos Corporation13$1,474
Astellas Pharma US Inc8$725
Microsurgical Technology, Inc.2$722
Eyevance Pharmaceuticals LLC27$553
Biogen6$494
Carl Zeiss Meditec, Inc.3$409
Mallinckrodt Hospital Products Inc.10$378
Merz Pharmaceuticals, LLC3$317
Topcon Healthcare, Inc.3$317
Biotissue Holdings Inc.5$308
Oyster Point Pharma, Inc.3$301
Lombart Brothers, Inc.1$272
Sight Sciences, Inc.3$246
Ocular Therapeutix, Inc.7$245
Lilly USA, LLC20$228
Coherus Oncology, Inc.1$149
Tearlab Corp2$149
Abbott1$142
Neurotech Pharmaceuticals, Inc.1$137
Kala Pharmaceuticals, Inc.1$123
Dompe US, Inc.1$99
Optos, Inc.1$77
Heidelberg Engineering, Inc.1$57
Tarsus Pharmaceuticals, Inc.3$40

How this compares

$2,140,360 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas →

Medicare billing

Part B allowed, 2024
$1,018,492
Medicare patients
479
Services billed
15,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other retina specialist in McAllen

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →